Cargando…

Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer

Immunotherapy has become a standard treatment in many cancers and it is based on three main therapeutic axes: immune checkpoint blockade (ICB), vaccination and adoptive cell transfer (ACT). If originally these therapies mainly focused on exploiting CD8 T cells given their role in the direct eliminat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saillard, Margaux, Cenerenti, Mara, Romero, Pedro, Jandus, Camilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147771/ https://www.ncbi.nlm.nih.gov/pubmed/34064410 http://dx.doi.org/10.3390/vaccines9050454

Ejemplares similares

The Era of Cytotoxic CD4 T Cells
por: Cenerenti, Mara, et al.
Publicado: (2022)

Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer
por: Cachot, Amélie, et al.
Publicado: (2021)

Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients
por: Rockinger, Georg Alexander, et al.
Publicado: (2020)

Harnessing Antitumor CD4(+) T Cells for Cancer Immunotherapy
por: Ben Khelil, Myriam, et al.
Publicado: (2022)

CD4+ T Cells: Multitasking Cells in the Duty of Cancer Immunotherapy
por: Richardson, Jennifer R., et al.
Publicado: (2021)

c-Met enforces proinflammatory and migratory features of human activated CD4(+) T cells
por: Benkhoucha, Mahdia, et al.
Publicado: (2021)

Functional and Phenotypic Plasticity of CD4(+) T Cell Subsets
por: Caza, Tiffany, et al.
Publicado: (2015)

Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
por: Pesce, Silvia, et al.
Publicado: (2020)

Editorial: CD4(+) T Cells in Cancer Immunotherapies
por: González-Navajas, José M., et al.
Publicado: (2021)

Distinct and shared gene expression for human innate versus adaptive helper lymphoid cells
por: Ercolano, Giuseppe, et al.
Publicado: (2020)

CD4(+) T Cells in Chronic Hepatitis B and T Cell-Directed Immunotherapy
por: Buschow, Sonja I., et al.
Publicado: (2021)

Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy
por: Raskov, Hans, et al.
Publicado: (2020)

Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment
por: Gomez-Cadena, Alejandra, et al.
Publicado: (2020)

Assessing the Impact of Persistent HIV Infection on Innate Lymphoid Cells Using In Vitro Models
por: Boulay, Aude, et al.
Publicado: (2023)

Revisiting the role of CD4(+) T cells in cancer immunotherapy—new insights into old paradigms
por: Tay, Rong En, et al.
Publicado: (2020)

Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021)

The Function of Memory CD8+ T Cells in Immunotherapy for Human Diseases
por: Choi, Hanbyeul, et al.
Publicado: (2023)

Journal for immunotherapy of cancer reviewer acknowledgement 2015
por: Romero, Pedro
Publicado: (2016)

Healthy and Patient Type 2 Innate Lymphoid Cells are Differently Affected by in vitro Culture Conditions
por: Falquet, Maryline, et al.
Publicado: (2021)

Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope
por: Baumgartner, Petra, et al.
Publicado: (2015)

Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
por: Mardis, Elaine R.
Publicado: (2019)

Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance
por: Hossain, Sultana Mehbuba, et al.
Publicado: (2023)

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
por: Vigano, Selena, et al.
Publicado: (2019)

Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4(+) and CD8(+) T cells for immunotherapy of cancer
por: Melssen, Marit M, et al.
Publicado: (2022)

CD137(+) T-Cells: Protagonists of the Immunotherapy Revolution
por: Ugolini, Alessio, et al.
Publicado: (2021)

Moving cancer immunotherapy forward through the Journal for ImmunoTherapy of Cancer (JITC)
por: Romero, Pedro
Publicado: (2019)

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

Dendritic cells direct circadian anti-tumour immune responses
por: Wang, Chen, et al.
Publicado: (2022)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy
por: Wo, Yu Jun, et al.
Publicado: (2019)

The CD112R/CD112 axis: a breakthrough in cancer immunotherapy
por: Zeng, Taofei, et al.
Publicado: (2021)

CD39/CD73/A2AR pathway and cancer immunotherapy
por: Xia, Chenglai, et al.
Publicado: (2023)

Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review
por: Bourbonne, Vincent, et al.
Publicado: (2022)

Development of Human ILCs and Impact of Unconventional Cytotoxic Subsets in the Pathophysiology of Inflammatory Diseases and Cancer
por: Calvi, Michela, et al.
Publicado: (2022)

An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
por: Chu, Dinh-Toi, et al.
Publicado: (2019)

CD24: A Novel Target for Cancer Immunotherapy
por: Panagiotou, Emmanouil, et al.
Publicado: (2022)

Dynamic CD8(+) T Cell Cooperation with Macrophages and Monocytes for Successful Cancer Immunotherapy
por: Vermare, Anaïs, et al.
Publicado: (2022)

Impact of Aging on the Frequency, Phenotype, and Function of CD161-Expressing T Cells
por: van der Geest, Kornelis S. M., et al.
Publicado: (2018)

When Aging Reaches CD4+ T-Cells: Phenotypic and Functional Changes
por: Moro-García, Marco Antonio, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4e52hvhkv8a0qujvnpjko41oab